SS Innovations International, Inc. (SSII) SEC Filings & Earnings Calls

Increased leverage and secured debt obligations may strain liquidity and increase default risk.

“Creation of a Direct Financial Obligation; secured convertible promissory note and security agreements.”

Regulatory approval uncertainty for SSi Mantra system

“FDA request for additional information indicates potential concerns; approval not guaranteed.”

Regulatory approval in US and EU is uncertain; timeline dependent on review outcomes.

“Estimated regulatory timelines for CE Mark and FDA 510(k) clearance; dependent on review.”

Lack of specific financial or operational details may indicate immateriality or cautious disclosure.

“No numbers or specific milestones mentioned in the excerpt.”

CFO departure could signal internal issues or leadership instability

“Departure of CFO effective August 21, 2026”

Going Concern Uncertainty

“Substantial doubt about ability to continue as a going concern due to recurring losses and negative cash flows.”

Regulatory Dependency

“R&D expenses increased due to clinical trials for FDA and CE Mark approvals; revenue dependent on regulatory clearances.”

Operating Losses

“Net loss of $2.66M in Q2 2026; accumulated deficit not disclosed but losses persist.”

Gross margin compression from 59.1% to 50.9% YoY; may indicate pricing pressure or cost increases

“Gross margin equaled 50.9%, compared to 59.1% in the second quarter of 2025.” · word for word

Net loss widened to $2.7M from $0.3M; profitability still distant despite revenue growth

“Net loss of $2.7 million, or $(0.01) per diluted share, compared to a net loss of $0.3 million” · word for word

Regulatory dependency: FDA 510(k) clearance and CE marking are critical for US/EU market entry

“We expect the U.S. Food and Drug Administration to complete its review of our 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027.” · word for word

Potential dilution from ATM offering of up to $50 million.

“aggregate offering price of up to $50 million” · word for word

Dependence on regulatory approvals for U.S. and EU market entry; FDA 510(k) review and CE marking still pending

“We expect the U.S. Food and Drug Administration to complete its review of our 510(k) premarket notification for the SSi Mantra this year” · word for word

Net loss continues though narrowing; company still pre-profitability

“Net loss of $3.6 million” · word for word

Going concern risk

“The Company is still in its initial years of revenue generation... may continue to incur losses for some time. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.” · word for word

Dependence on additional financing

“During the balance of the year ending December 31, 2026, the Company plans to raise additional capital through further private or public offerings of its securities.” · word for word

Regulatory approval risk

“Our financial performance is also dependent on our obtaining regulatory approvals in various regulated markets where we plan to sell our products.” · word for word

Cash burn risk: Net loss of $12.1M in FY2025 with only $3.2M cash on hand, though mitigated by $18.6M post-quarter capital raise.

“Cash and cash equivalents totaled $3.2 million. Net loss of $12.1 million for FY2025.”

Regulatory dependency: FDA and CE marking timelines are critical for US/EU market entry; any delay could impact growth trajectory.

“Company anticipates FDA review completion by mid-2026 and CE marking this year, but no guarantee of approval.”

Geographic concentration: Heavy reliance on Indian market for current revenue; international expansion still nascent.

“Company gained significant share of surgical robotics market in India; cumulative installed base across ten countries but India likely dominant.”

Going concern uncertainty

“These conditions raise substantial doubt about our ability to continue as a going concern.” · word for word

Capital dependency

“During 2026, the Company plans to raise additional capital through further private or public offerings.” · word for word

Regulatory approval risk

“There can be no assurance that we will receive CE certification.” · word for word

Preliminary unaudited revenue subject to change; financial close not completed.

“Revenue for 2025 is a preliminary unaudited estimate; subject to change upon completion of financial statement closing procedures.”

Regulatory approval timelines (FDA, CE) are estimates and may be delayed.

“Estimated Regulatory Timelines: FDA clearance H1 2026, EU CE Mark H1 2026 – dependent on review outcomes.”

High insider ownership (76.5%) may limit liquidity and corporate governance.

“Insider Ownership (4/14/25) 76.5%.” · word for word

Net loss persists despite revenue growth; cash burn may require future financing.

“Net loss of $3.7 million in Q3 2025; cash $5.7 million.”

Regulatory approval dependency for U.S. and EU market entry.

“510(k) submission anticipated Q4 2025; CE marking H1 2026.”

Going Concern Uncertainty

“These conditions raise substantial doubt about the Company’s ability to continue as a going concern.” · word for word

Dependence on Related-Party Financing

“Dr. Sudhir Srivastava, through Sushruta, provided the Company with $2,000,000 in financing on December 4, 2024, $5,000,000 in financing on January 3, 2025, $10,000,000 in financing on January 20, 2025, $5,000,000 in financing on January 30, 2025 and $8,000,000 in financing on March 19. 2025.” · word for word

Dilution Risk from Convertible Notes

“The One-Year Notes were convertible at the option of the holder into shares of our common stock at a conversion price of $1.38 per share ... As of September 30, 2025, all $30,000,000 in principal amount of One-Year Notes, together with $164,548 in interest thereon, were converted by Sushruta into 21,858,368 shares of our common stock.” · word for word